Fortis Group Advisors LLC decreased its position in Hims & Hers Health, Inc. (NYSE:HIMS – Free Report) by 70.9% during the 4th quarter, Holdings Channel.com reports. The fund owned 30,628 shares of the company’s stock after selling 74,707 shares during the quarter. Fortis Group Advisors LLC’s holdings in Hims & Hers Health were worth $994,000 at the end of the most recent quarter.
Other hedge funds have also added to or reduced their stakes in the company. Binnacle Investments Inc bought a new position in Hims & Hers Health in the third quarter valued at about $28,000. Silicon Valley Capital Partners bought a new position in Hims & Hers Health in the third quarter valued at about $48,000. Flagship Harbor Advisors LLC bought a new position in Hims & Hers Health in the fourth quarter valued at about $28,000. Bogart Wealth LLC boosted its holdings in Hims & Hers Health by 235.8% in the fourth quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock valued at $29,000 after acquiring an additional 632 shares during the last quarter. Finally, Smartleaf Asset Management LLC boosted its holdings in Hims & Hers Health by 44.7% in the third quarter. Smartleaf Asset Management LLC now owns 916 shares of the company’s stock valued at $54,000 after acquiring an additional 283 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.
Hims & Hers Health Trading Up 4.1%
NYSE HIMS opened at $23.98 on Friday. The firm has a market cap of $5.47 billion, a P/E ratio of -266.43, a P/E/G ratio of 21.68 and a beta of 2.43. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.69 and a quick ratio of 1.56. The stock’s 50-day moving average is $24.08 and its 200-day moving average is $28.13. Hims & Hers Health, Inc. has a one year low of $13.74 and a one year high of $70.43.
Analyst Ratings Changes
Several equities analysts have weighed in on HIMS shares. Jefferies Financial Group set a $24.50 target price on Hims & Hers Health in a research note on Tuesday, May 12th. BTIG Research reissued a “neutral” rating on shares of Hims & Hers Health in a research note on Tuesday, May 12th. Citigroup increased their target price on Hims & Hers Health from $24.00 to $28.00 and gave the company a “neutral” rating in a research note on Tuesday, May 12th. Zacks Research raised Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 25th. Finally, Bank of America cut their target price on Hims & Hers Health from $30.00 to $28.00 and set a “neutral” rating on the stock in a research note on Tuesday. Four research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Hims & Hers Health presently has a consensus rating of “Hold” and an average price target of $29.37.
View Our Latest Stock Analysis on HIMS
Insiders Place Their Bets
In other news, insider Soleil Boughton sold 9,463 shares of the firm’s stock in a transaction dated Monday, April 20th. The stock was sold at an average price of $30.00, for a total transaction of $283,890.00. Following the sale, the insider owned 299,368 shares of the company’s stock, valued at $8,981,040. This trade represents a 3.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Irene Becklund sold 5,529 shares of the stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $24.69, for a total value of $136,511.01. Following the transaction, the insider owned 8,752 shares of the company’s stock, valued at approximately $216,086.88. The trade was a 38.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 212,807 shares of company stock worth $5,473,644. 11.76% of the stock is owned by company insiders.
Trending Headlines about Hims & Hers Health
Here are the key news stories impacting Hims & Hers Health this week:
- Positive Sentiment: Hims & Hers expanded its GLP-1 offering in Canada by launching access to generic semaglutide, its first international generic GLP-1 product. The move could help broaden the company’s customer base and strengthen its growth story outside the U.S. Hims & Hers Brings First-Time Access to Generic Semaglutide to Canada
- Positive Sentiment: The Canadian semaglutide launch reinforces Hims & Hers’ broader international expansion strategy and ability to offer lower-cost GLP-1 treatments in a market where affordability has been a barrier. Hims & Hers launches generics for Novo’s semaglutide in Canada
- Neutral Sentiment: Analysts continue to debate the stock’s setup after the earnings miss, with some noting the long-term GLP-1 opportunity still intact even as near-term sentiment remains cautious. The Silver Lining of Last Week’s Hims and Hers Earnings Miss
- Negative Sentiment: Investor concern about dilution from the company’s recent convertible note offering has weighed on the stock, offsetting some of the optimism around new capital and expansion plans. Hims & Hers stock slips as dilution fears outweigh new capital
- Negative Sentiment: Sentiment remains hurt by the recent Q1 earnings miss and softer-than-expected revenue, which reminded investors that execution risk is still high despite the company’s strategic pivot in weight-loss offerings. 5 Revealing Analyst Questions From Hims & Hers Health’s Q1 Earnings Call
About Hims & Hers Health
Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.
The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.
Featured Stories
- Five stocks we like better than Hims & Hers Health
- Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending
- As Small-Cap Outperformance Continues, These 2 ETFs Provide Exposure
- Silicon Shake-Up: The AI Trade Is Moving Beyond NVIDIA
- The Silver Lining of Last Week’s Hims & Hers Earnings Miss
Want to see what other hedge funds are holding HIMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hims & Hers Health, Inc. (NYSE:HIMS – Free Report).
Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.
